875110-43-3

Basic information

• Product Name: Benzene, 1-(diethoxymethyl)-4-(2,2-difluoroethenyl)-
• CAS NO: 875110-43-3
• Molecular Formula: C13H16F2O2
• Molecular Weight: 242.266
• Mol File: 875110-43-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(diethoxymethyl)-4-(2,2-difluoroethenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(diethoxymethyl)-4-(2,2-difluoroethenyl)-(875110-43-3)
• EPA Substance Registry System: Benzene, 1-(diethoxymethyl)-4-(2,2-difluoroethenyl)-(875110-43-3)

Safety Data

• Hazardous Substances Data: 875110-43-3(Hazardous Substances Data)

Upstream product

• 81172-89-6 terephthalaldehyde mono(diethylacetal) 
• 94993-99-4 diethyl difluoromethylphosphonate lithium salt 

Downstream Products

• 875110-45-5 4-(2,2-difluorovinyl)benzaldehyde 
• 875110-50-2 2-[4-(2,2-difluorovinyl)benzyl]phenol 
• 875110-47-7 (2-Benzyloxyphenyl)-[4-(2,2-difluorovinyl)phenyl]methanol 
• 875110-49-9 1-benzyloxy-2-[4-(2,2-difluorovinyl)-benzyl]benzene 

Relevant articles and documents

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.